Highlights
- Alcidion reported FY26 Revenue of AUD 51.6 million versus AUD 40.8 million previously.
- FY26 EBITDA reached AUD 6.2 million, while Operating Cash Flow was AUD 6.8 million.
- The company recorded AUD 78.5 million in contract sales and renewals.
- Its University Hospitals Sussex agreement expanded the UK electronic patient record opportunity.
Alcidion Group Ltd (ASX:ALC) supplies clinical software to healthcare organisations, where complex procurement decisions and lengthy implementation cycles can shape the timing of revenue. Its latest reported full year provides a more specific picture than general commentary on digital healthcare demand. For the year ended 30 June 2026, revenue increased to AUD 51.6 million from AUD 40.8 million, alongside a larger contracted sales pipeline and cash generation.
Revenue Growth and the Cash Conversion Test
FY26 EBITDA was AUD 6.2 million compared with AUD 4.8 million in the previous year, according to the annual report. Operating cash flow of AUD 6.8 million exceeded the prior AUD 5.8 million, and customer cash receipts rose to AUD 56.1 million from AUD 50.9 million. These measures should be considered together: sales expansion is more persuasive when collections and operating cash generation also improve. They do not, however, establish that every newly signed contract has reached its normal Operating Revenue profile.
The year-end cash balance was AUD 20.6 million, against AUD 17.7 million a year earlier. This gives the Business resources for product Investment and deployment obligations, although cash demands can vary materially with implementation schedules. Annual Recurring Revenue was AUD 31.9 million; this is distinct from total annual revenue because not every contract component is recurring.
NHS Rollouts Bring Delivery Obligations
UK hospital programmes are an important element of the commercial picture. Alcidion signed a seven-year electronic patient record agreement with University Hospitals Sussex NHS Foundation Trust after being selected as preferred supplier. The programme links the company’s hospital technology offering to a multi-year customer relationship rather than a one-off licence event. As implementations progress, the distinction between contract value, contracted revenue and revenue recognised in the accounts remains essential.
The company has also highlighted expanded work with North Cumbria Integrated Care and Leidos Australia. Contract extensions can broaden the installed software footprint, but contractual commitments still need to be converted through delivery, acceptance and support activity. Comparing customer deployments with subsequent cash collections offers a practical test of progress.
Clinical Software and Regulated AI
Miya Precision supports clinical information and workflow processes, positioning Alcidion within hospital systems that require integration with existing records and staff practices. During FY26, the company also reported medical-device registration of its Concept Detection capability in Australia and the United Kingdom. That regulatory milestone provides a framework for deployment of the AI-enabled feature; it is not evidence that every customer has adopted it.
What the Contract Mix Means for Risk
The FY26 report recorded AUD 78.5 million in total contract value from new sales and renewals, up from AUD 73.8 million previously. Contract value indicates commercial commitments over multiple periods, not an amount recognised immediately as revenue. Implementation delays, changing hospital priorities, interoperability requirements and public-sector budgeting may influence the pace at which these commitments contribute to the income statement.
A further consideration is product development spending: Alcidion must maintain reliability and compliance while supporting deployments across healthcare systems. Its financial trajectory therefore depends on execution as much as the number or headline value of agreements.
Key Insights
Alcidion’s FY26 figures connect higher revenue with improved EBITDA, operating cash generation and contract activity. The University Hospitals Sussex agreement and broader Miya Precision portfolio add implementation opportunities, while AUD 31.9 million in annual recurring revenue shows the importance of ongoing customer relationships. The relevant measures are future contract delivery, cash collections and software adoption rather than headline contract values alone.


_11_16_2026_07_52_44_870464.jpg)



Please wait processing your request...